SkylineDx Presents Pioneering Data at ASH 2023: SKY92 Risk Stratification in Multiple Myeloma Patients

ROTTERDAM, Netherlands and SAN DIEGO, Dec. 8, 2023 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics is looking forward to the release of new data during the American Society of Hematology (ASH) 2023 Annual Meeting. Dr….

Click here to view original post